|
|
|
基本情報
| 氏名 |
秋元 雅之 |
| 氏名（カナ） |
アキモト マサユキ |
| 氏名（英語） |
Akimoto Masayuki |
| 所属 |
薬学部 医療薬学科 |
| 職名 |
教授 |
| researchmap研究者コード |
|
| researchmap機関 |
|
- Drug-carrier Property of albumin microspheres in chemotherapy Ⅲ. Effect of microsphere-entrapped 5-fluorouracil on Ehrlich ascites carcinoma in mice Sugibayashi K, Akimoto M, Morimoto Y, Nadai T, and Kato Y. 共著 J. Pharm. Dyn. 2巻 1979/06
- 5-Fluorouracilを含有したアルブミン小球体のEhrlich腹水癌および固形癌に対する持続的抗腫瘍効果に関する研究 秋元雅之 単著 城西大学大学院薬学研究科 (修士論文) 1980/03
- Drug-carrier property of albumin microspheres in chemotherapy Ⅳ. Antitumor effect of single-shot or multiple-shot administration of microsphere-entrapped 5-fluorouracil on Ehrlich ascites or solid tumor in mice. Morimoto M, Akimoto M, Sugibayashi K, Nadai T, and Kato Y. 共著 Chem. Pharm. Bull. 1980/10
- Spectrophotometric Analysis for Fluolouracil in Biological Fluids. Morimoto Y, Akimoto M, Sugibayashi K, Nadai T and KatoY. 共著 Pharmazie 1981/02
- Dispersion state of protein-stabilized magnetic emulsions. Morimoto Y, Akimoto M and Yotsumoto Y. 共著 Chem. Pharm. Bull. 1982/08
- Use of magnetic emulsion as a novel drug carrier for chemotherapeutic agents. Akimoto M and Morimoto Y. 共著 Biomaterials 1983/01
- Magnetic guidance of ferro-colloid-entrapped emulsion for site-specific drug delivery. Morimoto Y, Sugibayashi K and Akimoto M 共著 Chem. Pharm. Bull. 1983/01
- 制癌剤含有磁性エマルションの調製と癌化学療法への応用 秋元雅之 単著 城西大学大学院薬学研究科 (博士論文) 1984/03
- Application of magnetic emulsions for sustained release and targeting of drugs in cancer chemotherapy. Akimoto M, Sugibayashi K and Morimoto Y. 共著 J. Controlled Release 1985/04
- Intestinal absorption enhancement of Coenzyme Q10 with a lipid microsphere. Ozawa Y, Mizushima Y, Koyama I, Akimoto M, Yamagata Y, Hayashi H and Murayama H. 共著 Arzneim-Forsch./Drug Res. 1986/04
- Evaluation of sustained-release granules of Chlorphenesin Carbamate in dogs and humans. Akimoto M, Furuya A, Maki T, Yamada K, Suwa T and Ogata H. 共著 Int. J. Pharm. 1993/04
- Release and absorption characteristics of chlorphenesin carbamate sustained-release formulations:in vitro-in vivo and in vivo dog-human correlations. Akimoto M, Furuya A, Nakamura M, Maki T, Yamada K, Suwa T and Ogata H. 共著 Int. J. Pharm. 1995/02
- Evaluation of gastrointestinal transit controlled-beagle dogs as a suitable animal model for bioavail- ability testing of sustained-release acetaminophen dosage form. Yamada K, Furuya A, Akimoto M, Maki T, Suwa T and Ogata H. 共著 Int. J. Pharm. 1995/09
- Retention mechanism of imidazoles in connective tissue Ⅰ. Binding to elastin. Ohta K, Yamaguchi J, Akimoto M, Fukushima K, Suwa T and Awazu. 共著 Drug Metab．Dispos． 1996/12
- Retention mechanism of imidazoles in connective tissue Ⅱ. Activation of Imidazoles in cuproascorbate system for irreversi ble binding formation with aortic tissue in vitro. Ohta K, Yamaguchi J, Akimoto M, Kohno Y, Fukushima K, Suwa T And Awazu S. 共著 Biol. Pharm. Bull. 1998/03
- Retention mechanism of imidazole in connective tissue Ⅲ. Aldehyde adducts formation of a 4(5H) (or 5(4H))- imidazolone product in vitro. Ohta K, Yamaguchi J, Akimoto M, Kohno Y, Fukushima K, Suwa T And Awazu S. 共著 Biol. Pharm. Bull. 1998/09
- Pibutidine Hydrochloride, 3-amino-4-[[(Z)-4-[[4-(piperidinomethyl)-2-pyridyl] oxy]-2- butenyl]amino ]-3-cyclobutene-1,2-dione monohydro- chloride (IT-066) の体内動態(第7報)：シクロブテン環14C標識体のラットにおける代謝. 新井正行，長瀬靖子，佐々木毅典，加藤幸司，秋元雅之，樋口昭平 共著 『薬理と治療 』 27巻4号 1999/04
- Pibutidine Hydrochloride, 3-amino-4- [[(Z)-4-[[4-(piperidino-methyl)-2-pyridyl]-oxy]-2-butenyl]amino]-3- cyclobutene-1,2-dione monohydro- chloride (IT-066) の体内動態(第2報)：ラットにおける経口投与後の胎児・乳汁移行性および反復投与時の体内動態. 新井正行，長瀬靖子，佐々木毅典，太田勝二，片岡賢司，伊藤千寿，秋元雅之，樋口昭平 共著 『薬理と治療 』 1999/04
- Pibutidine Hydro- chloride, 3-amino-4- [[(Z)-4-[[4-(piperidinomethyl)-2-pyridyl]-oxy]-2-butenyl]amino]-3-cyclobutene-1,2-dione monohydrochloride (IT-066) の体内動態(第1報)：ラットにおける単回投与後の吸収、分布および排泄. 新井正行，長瀬靖子，佐々木毅典，太田勝次，片岡賢司，秋元雅之，樋口昭平 共著 『薬理と治療 』 1999/04
- Pibutidine Hydro- chloride, 3-amino-4- [[(Z)-4-[[4-(piperidinomethyl)-2-pyridyl] oxy]-2-butenyl]amino]-3-cyclobutene-1,2- dione monohydro- chloride (IT-066) の体内動態(第6報)：シクロブテン環14C標識体のラットにおける吸収、分布および排泄. 新井正行，長瀬靖子，佐々木毅典，太田勝次，秋元雅之，樋口昭平 共著 『薬理と治療 』 1999/04
- Pibutidine Hydro- chloride, 3-amino-4- [[(Z)-4-[[4-(piperidino-methyl)-2-pyridyl]-oxy]-2-butenyl]amino]-3-cyclobutene-1,2-dione monohydro- chloride (IT-066) の体内動態(第4報)：ラットにおける単回投与後の吸収、分布および排泄. 新井正行，長瀬靖子，神宮茂司，秋元雅之，樋口昭平 共著 『薬理と治療 』 1999/04
- Pibutidine Hydro- chloride, 3-amino-4- [[(Z)-4-[[4-(piperidino-methyl)-2-pyridyl]-oxy]-2-butenyl]amino]-3-cyclobutene-1,2-dione monohydro- chloride (IT-066) の体内動態(第3報)：イヌにおける単回投与後の吸収、分布および排泄. 新井正行，長瀬靖子，秋元雅之，樋口昭平 共著 『薬理と治療 』 1999/04
- Pibutidine Hydro- chloride, 3-amino-4- [[(Z)-4-[[4-(piperidino-methyl)-2-pyridyl]-oxy]-2-butenyl]amino]-3-cyclobutene-1,2- dione monohydro- chloride (IT-066) の体内動態(第5報)：ラットにおける代謝. 新井正行，長瀬靖子，佐々木毅典， 神宮茂司，山口順一，河原志都子， 秋元雅之，樋口昭平 共著 『薬理と治療 』 27巻4号 1999/04
- Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Suzuki A, Iida I, Tanaka F, Akimoto M, Fukushima K, Tani M, Ishizaki T and Chiba K. 共著 Drug Metab. Dispos． 1999/11
- Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Akimoto M, Nagahata, N, Furuya A, Fukushima, Higuchi S and Suwa T. 共著 Eur. J. Pharm. Biopharm. 2000/03
- Population pharmacokinetics and pharmacodynamics of TS- 943 for selective nonpeptide platelet glycoprotein 2b/3a receptor antagonist in normal healthy subjects. Furuya A, Kato N, Jingu S, Akimoto M, Higuchi S, Suwa T and Ogata H. 共著 Clin. Pharmacol. Ther. 2000/05
- Pharmacokinetic and pharmacody- namic analysis of TS-943, a selective nonpeptide platelet glycoprotein (GP2b/ 3a) 2b/3a receptor antagonist, using a nonlinear mixed- effect model in dogs. Furuya A, Nozawa M, Gotoh J, Jingu S, Akimoto M, Higuchi S, Suwa T and Ogata H. 共著 J. Pharm. Pharmacol. 2002/10
- CYP isoforms involved in the metabolism of Clarithromycin: Comparison between the identifycation from disappearance rate and that from formation rate of metabolites Akio SUZUKI, Izumi IIDA, Mitsuyo HIROTA, Masayuki AKIMOTO, Shohei HIGUCHI, Toshio SUWA, Masayoshi Tani, Takashi ISHIZAKI, and Kan CHIBA 共著 Drug Metab. Pharmacokin. 2003/09
- Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943 A. Furuya, N. Kato, S. Jingu, M. Akimoto, O. Kasai, T. Suwa, M. Sato, and H. Ogata 共著 Eur. J. Drug Metab. Pharmakokin. 2003/10
- S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. N. Ohmi, H. Yoshida, H. Endo, M. Hasegawa, M. Akimoto and S. Higuchi. 共著 Xenobiotica. 2003/12
- Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5’-hydroxylation. Izumi Iida, Atsunori Miyata, Masayuki Arai, Mitsuyo Hirota, Masayuki Akimoto, Shohei Higuchi, Kaoru Kobayashi, Kan Chiba. 共著 Drug Metab. Dispos. 2004/01
- The in vitro metabolism of desgly-midodrine, an active metabolite of prodrug midodrine by human liver microsomes. Masayuki Akimoto, Izumi Iida, Hiroki Itoga, Atsunori Miyata, Shizuko Kawahara, and Yoshiro Kohno. 共著 Eur. J. Drug Metab. Pharmakokin. 2004/09
- Conversion of FAD and Riboflavin in Plasma: Effects of Measuring Method Masayuki Akimoto, Yuko Sato, Toshimi Okubo, Hiroaki Todo, Tetsuya Hasegawa, Kenji Sugibayashi . 共著 Biol. Pharm. Bull. 2006/08
- Pharmacokinetic Profile of Flavin Adenine Dinucleotide, and Riboflavin Following Intravenous Administration of Riboflavin or Its Coenzymes in Rats. Masayuki Akimoto, Yuko Sato, Eiichi Nemoto, Hiroaki Todo, Tetsuya Hasegawa, and Kenji Sugibayashi. 共著 J. Health Sci., 2007/06
- 「消費者のためのビタミンC製品情報」 秋元雅之、根本英一、長谷川哲也. 共著 ビタミン 2007/08
- Analysis of skin disposition of flurbiprofen after topical application using dual agar gel discs-inserted rats. Tetsuya Hasegawa, Asako Kawazome, Go Yanagimoto, Teruaki Hayashi, Toshinobu Seki, Masayuki Akimoto, Hiroaki Todo, Kenji Sugibayashi. 共著 Biol. Pharm. Bull. 2007/11
- アセトアミノフェン小児用ドライシロップ剤の味覚評価（苦味マスキングに関する評価 第１報） 加賀谷隆彦、井上岳、綾美咲、松本かおり、長谷川哲也、秋元雅之、厚田幸一郎、杉林堅次. 共著 『薬剤学』 2008/10
- Why does a hydrophilic drug permeate skin, although it is not soluble in white petrolatum. Hydrophilic drug release and skin permeation from ointments. Hiroshi Ishii, Hiroaki Todo, Akira Terao, Tetuya Hasegawa, Masayuki Akimoto, Kouichi Oshima, Kenji Sugibayashi. 共著 Drug Dev. Ind. Pharm. 2009/11
- 『苦味物質に及ぼすゼリー状嚥下補助食品のマスキング効果』（苦味マスキングに関する評価 第2報） 加賀谷隆彦、井上岳、綾美咲、松本かおり、長谷川哲也、濱田ひかり、秋元雅之、厚田幸一郎、杉林堅次. 共著 FOOD FUNCTION 2010/01
- アンブロキソール塩酸塩小児用ドライシロップ製剤の味覚評価 後味に関する評価 第１報 加賀谷隆彦, 綾 美咲, 秋元雅之, 厚田幸一郎. 共著 医学と薬学 2010/04
- 「高性能GC×GC-TOFMSを用いたラベンダー精油主成分の安定性評価」 長谷川哲也、松本かおり、秋元雅之、矢部敏明、土屋文彦、川口健夫. 共著 『J. Holistic Sci.』 2010/10
- 唾液中アミラーゼ活性を指標としたオレンジ・スイート芳香浴のストレス軽減効果の評価 毛塚綾乃、中部円香、松本かおり、長谷川哲也、秋元雅之 . 共著 J. Holistic Sci. 2011/04
- Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin Gen Hirano, Hiroto Izumi, Yoshihiro Yasuniwa, Shohei Shimajiri, Wang Ke-Yong, Yasuyuki Sasagiri, Hitoshi Kusaba, Kaori Matsumoto, Tetsuya Hasegawa, Masayuki Akimoto, Koichi Akashi, Kimitoshi Kohno. 共著 Int. J. Oncol. 2011/04
- In Vitro characterization of the cyto-chrome P450 isoforms involved in the metabolism of 6-methoxy-2-naphthylacetic acid, an active metabolite of the prodrug nabumetone. Kaori Matsumoto, Eiichi Nemoto, Tetsuya Hasegawa, Masayuki Akimoto, Kenji Sugibayashi. 共著 Biol. Pharm. Bull. 2011/05
- 薬学教育モデル・コアカリキュラムに準拠した六年制薬学教育における学生の達成感に関する自己評価の一例 An example of self-evaluation of a sense of achievement by students in 6-year pharmacy school with the model core curriculum of pharmaceutical education 新垣知輝、小柳順一、中村洋、平田隆弘、太田篤胤、秋元雅之、白幡晶、光本篤史. 共著 薬学雑誌 yakugaku zasshi 2013/01
- 「唾液中アミラーゼ活性を指標としたラベンダー・アングスティフォリア芳香浴のストレス軽減効果の評価」 中部円香, 毛塚綾乃, 松本かおり, 長谷川哲也, 秋元雅之. 共著 The Journal of Holistic Sciences 2013/04
- The inhibitory Effect of kakkonto, Japanese traditional (kammpoo)medicine, on brain penetration of Oseltamivir carboxylate in Mice Reduced Blood-Brain Barrier Funcion Ohara K, Oshima S, Fukuda N, Ochiai Y, Maruyama A, Kanamuro A, Negishi A, Honma S, Oshima S, Akimoto M, Takenaka S, and Kobayashi D. 共著 Evidence-Based Complementary and Alternative Medicine 2015/02
- Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Matsumoto K, Hasegawa T, Kamei T, Koyanagi J, Takahashi T, Akimoto M, Sugibayashi K 共著 Eur. J. Drug Metab. Pharmacokinet. 2015/08
- 有色米のポリフェノール含量と抗酸化能の測定 菊池 奈緒美, 松本 かおり, 堀 聖一, 長谷川 哲也, 秋元 雅之. 共著 J. Holistic Sci. 2016/10
- Comparative Release Studies on Suppositories using the Basket, Paddle, Dialysis Tubing, and Flow-Through Cell Methods. I. Acetaminophen in a lipophilic base suppository Seiichi Hori, Tsubasa Kawata, Sanae Kogure, Shinako Yabu, Kenji Mori, Masayuki Akimoto. 共著 Pharmaceutical Development & Technology 2017/01
- （研究ノート）坐剤針入度試験装置を使用した直腸適用坐剤の軟化時間測定 Hori S, Mori K, Matsumoto K, Hasegawa T, Akimoto M. 共著 城西国際大学大学院紀要 2017/03
- LPS誘発血液脳関門機能低下マウスのBBB機能および死亡率に対する漢方製剤投与の影響 大原厚佑、小林大介、秋元雅之. 共著 城西国際大学大学院紀要 2017/03
- LPS誘発血液脳関門機能低下マウスにおけるイブプロフェンの脳移行性に及ぼす葛根湯併用の影響 大原厚佑、小林大介、秋元雅之. 共著 城西国際大学大学院紀要 2017/03
- The in vitro release of indomethacin from suppositories: Effects of bases and comparison of different dissolution methods. Kenji Mori, Seiichi Hori, Tubasa Kawata, Sanae Kogure, Kaori Matsumoto, Tetsuya Hasegawa, and Masayuki Akimoto. 共著 Chem. Pharm. Bull． 2017/11
- Determination of the absolute configuration of the nabumetone metabolite 4-(6-methoxy-2-naphthyl) butan-2-ol using the chiral derivatizing agent, 1-fluoroindan-1-carboxylic acid. Tomoyo Kamei, Yuta Kimura, Jyunichi Koyanagi, Kaori Matsumoto, Tetsuya Hasegawa, Masayuki Akimoto, TamikoTakahashi. 共著 Chem. Pharm. Bull. 2019/01
- ブルーベリー果実抽出液のDPPHラジカル消去活性評価に及ぼす測定方法の影響ーHPLC法とUV-VIS法の比較ー 芝田裕磨、大原厚裕、武井千弥、松本かおり、長谷川哲也、秋元雅之、光本篤史. 共著 城西国際大学大学院紀要 2019/03
- Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, Chihiro Takei, and Masayuki Akimoto. 共著 Journal of Pharmaceutical Investigation, 2020/02
- A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, Chihiro Takei, Tomoyo Kamei, Jyunichi Koyanagi, Tamiko Takahashi, and Masayuki Akimoto. 共著 Xenobiotica 2020/04
- Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, Tomoyo Kamei, Jyunichi Koyanagi, and Masayuki Akimoto. 共著 Xenobiotica 2021/01
- Total Anthocyanin Content, Total Phenolic Content, and Antioxidant Activity of Various Blueberry Cultivars Grown in Togane, Chiba Prefecture, Japan. Yuma Shibata, Kosuke Ohara, Kaori Matsumoto1, Tetsuya Hasegawa, Masayuki Akimoto. 共著 J Nutr. Sci. Vitaminol. 2021/06
- 東金産有色米エタノール抽出液のポリフェノール含量と糖質分解酵素阻害活性に関する研究. 芝田裕磨, 小西久実, 大原厚祐, 松本かおり, 長谷川哲也,秋元雅之. 共著 J Holistic Sci 2021/10
- Evaluation of the Palatability of Isosorbide by Human Gustatory Sensation and Electric Taste Sensor 共著 J Drug Interaction Res（医薬品相互作用研究）
2021/12
- ケトプロフェン貼付剤の先発医薬品及び後発医薬品の臨床における同等性の検討 小林江梨子、森健二、大原厚祐、篠塚優斗、小川真央、武井千弥、小野寺隆芳、丸宗孝、秋元雅之、佐藤信範 共著 医薬品相互作用研究 2023/02
- Weak Inhibitory Effects of Anthocyanins on Human Aldehyde Oxidase Activity: An in vitro study. Yuma Shibata, Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, and Masayuki Akimoto 共著 J Nutr. Sci. Vitaminol. 2023/02
|
